



EDITOR

Jeffrey L. Susman, MD,
University of Cincinnati

ASSOCIATE EDITORS

Cheryl A. Flynn, MD, MS, State
University of New York, Syracuse
John Hickner, MD, MSc, University of
Chicago Pritzker School of Medicine
James Stevermer, MD, MSPH, University
of Missouri, Columbia (*Clinical Inquiries*)
Richard P. Usatine, MD, University
of Texas Health Sciences Center
at San Antonio (*Photo Rounds*)

CONSULTING EDITOR

Bernard Ewigman, MD, MSPH,
University of Chicago Pritzker School
of Medicine (*Clinical Inquiries*)

ASSISTANT EDITORS

Burt Banks, MD, East Tennessee State
University, Bristol
Doug Campos-Outcalt, MD, MPA,
University of Arizona, Phoenix
Mark R. Ellis, MD, MSPH, Cox Family
Practice Residency, Springfield, Mo
Charissa Fotinos, MD, University of
Washington, Seattle
Gary N. Fox, MD, St. Vincent Mercy
Medical Center, Toledo, Ohio
Rick Guthmann, MD, University of
Illinois, Chicago
Eric Henley, MD, MPH, University of
Illinois, Rockford
Keith B. Holten, MD, University of
Cincinnati
Kevin Y. Kane, MD, MSPH, University
of Missouri, Columbia
Gary Kelsberg, MD, FAAFP, University
of Washington, Renton
Valerie J. King, MD, MPH, Oregon
Health & Science University, Portland
Todd D. McDiarmid, MD, Moses Cone
Family Medicine Residency, Greensboro, NC
Jon O. Neher, MD, University of
Washington, Renton
M. Norman Oliver, MD, MA, University
of Virginia, Charlottesville
Audrey Paulman, MD, MMM,
University of Nebraska College
of Medicine, Omaha
Paul M. Paulman, MD, University of
Nebraska College of Medicine, Omaha
Goutham Rao, MD, MPA, University of
Pittsburgh
Rick Ricer, MD, University of Cincinnati
Fred Tudiver, MD, East Tennessee State
University, Johnson City

EDITORIAL BOARD

Frederick Chen, MD, MPH, University of
Washington, Seattle
Larry Culpepper, MD, MPH, Boston
University Medical Center, Boston, Mass
John W. Ely, MD, MSPH, University of
Iowa College of Medicine, Iowa City
Linda French, MD, Michigan State
University, East Lansing
Theodore G. Ganiats, MD, University
of California—San Diego Health Outcomes
Assessment Program, La Jolla, Calif
Paul Gordon, MD, University of Arizona,
Tucson
Caryl J. Heaton, DO, University of Medicine
and Dentistry of New Jersey, Newark
Fred Miser, MD, MA, Ohio State
University, Columbus
Kevin Peterson, MD, MPH, University of
Minnesota, St Paul
Kendra Schwartz, MD, MSPH, Wayne
State University, Detroit, Mich
Douglas R. Smucker, MD, MPH, Moses
Cone Family Medicine Residency,
Greensboro, NC
Jack Westfall, MD, University of Colorado

Direct editorial information and inquiries to:

EDITORIAL OFFICE

Health Professions Building, Department
of Family Medicine, PO Box 670582,
Cincinnati, OH 45267-0582.
Telephone: (513) 558-4021.

PUBLISHING OFFICES

Dowden Health Media, Inc,
110 Summit Avenue, Montvale, NJ
07645.
Telephone: (201) 782-5735.
Fax: (201) 505-5890

Rosiglitazone: Failure of oversight or demons imagined?

Hey doc, I hear you're trying to kill me with that diabetes drug you got me on."

So began my conversation with MJ, an overweight man with type 2 diabetes who, despite counseling, resolutely smokes a pack of cigarettes a day.

Perhaps you've had a similar encounter with a patient of yours who's taking rosiglitazone (Avandia). As I write this, the news is awash with reports of the FDA Panel that voted 20-3 that rosiglitazone may increase the chances of a heart attack and 22-1 to keep the drug on the market. Small solace to the 7 million MJs worldwide who see some irony in remaining on a drug that has caused a "virtual public health emergency."¹

So where do we go from here?

Discussing the matter with patients is not easy, given that the facts are not black and white. Taken together, the data from the original meta-analysis by Nissen,² the analysis of the RECORD trial,³ and GlaxoSmithKline's own analysis⁴ do not conclusively demonstrate either cardiovascular risk or benefit from rosiglitazone or provide a robust comparison to a full range of alternative therapies. While most experts believe (as do I) that it is unlikely that rosiglitazone reduces cardiac events in patients with diabetes, what we actually advise individual patients remains more challenging. Consider:

1. **The magnitude of increased risk** and variation of risk for classes of patients is largely unknown. With rosiglitazone's association with congestive heart failure (see the RECORD study), it would seem prudent to steer away from peroxisome-proliferator-activated receptor (PPAR) agonists in patients with existing heart failure, or those who are at high risk.
2. **The unintended consequences** of switching from rosiglitazone to another agent, including factors such as new side effects, nonadherence, or relative worsening of glycemic control may obviate any increased risk in cardiovascular events.
3. **The timing of risk is uncertain.** A more robust time to event analysis is not possible given the data that's available in the public domain. Thus, we do not know if cardiovascular risk is increased early, after a certain time, or if it escalates over time.
4. **There is an alternative.** Another PPAR, pioglitazone (Actos), may reduce macrovascular complications. However, the most robust trial—the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE)⁵—has been criticized for its methodology.

With all of this in mind, I'm going to counsel patients on the risks and benefits of ongoing rosiglitazone use and lean towards switching to another alternative.


CONTINUED ON PAGE 703

I'm also going to advocate for change. I believe we need to:

- **develop a robust drug surveillance system.** And what better way to uncover drug side effects than equipping every family physician with electronic health records? I say ditch that new bomber, cut industry subsidies, and give us a system for capturing patient level data throughout our healthcare system.
- **stop approving drugs based on surrogate outcomes** such as glycemic control and require patient-oriented outcomes such as cardiovascular events or all cause mortality before giving new drugs the green light. *The Journal of Family Practice* has been a leader in emphasizing patient-oriented outcomes— isn't it time the FDA did the same?
- **require all pharmaceutical companies to publish patient level data** from their trials, including all results (eg, side effects) from preliminary trials. It is clear that at least one other PPAR agonist in development was abandoned because of its association with cardiovascular events. Thus, it should be no surprise that such information might emerge during post-marketing surveillance.

- **stop demonizing pharmaceutical companies** and condemning the FDA, while ignoring the lamentable state of healthcare in the US.

Isn't it time Congress, the FDA, Pharma, our major insurers, big business, and yes—family physicians—unite to foster a health system built on equity, evidence, effectiveness, and efficiency?



Jeff Susman, MD, Editor
jfp@famned.uc.edu

REFERENCES

1. Carr D. Call the doctor. *The New York Times*, June 11, 2007. Available at: www.nytimes.com/2007/06/11/business/11carr.html?ex=1187150400&en=2a7b90ca974f0750&ei=5070. Accessed August 13, 2007.
2. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *N Engl J Med* 2007; 356:2457–2471.
3. Home PD, Pocock SJ, Beck-Nielsen HB, et al. Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. *N Engl J Med* 2007; 357:28–38.
4. GlaxoSmithKline. Study no ZM2005/00181/01: Avandia cardiovascular event modeling project. Available at: ctr.gsk.co.uk/summary/rosiglitazone/III_cvmodeling.pdf. Accessed August 8, 2007.
5. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 2005; 366:1279–1289.

INTRODUCING

THE JOURNAL OF FAMILY PRACTICE

SPECIAL EDITION:
Current Clinical Practice

Promoting Quality, Safety, and Efficiency

This series of special editions of **THE JOURNAL OF FAMILY PRACTICE** will address topics that focus on the important nonclinical aspects of medical practice, including:

- **PAY-FOR-PERFORMANCE**
- **RISK MANAGEMENT**
- **MEDICAL ETHICS**
- **ELECTRONIC MEDICAL RECORDS**

Each quarterly issue will be loaded with opportunities for **FREE CME credits** in therapeutic areas.

LOOK FOR THE PREMIER ISSUE IN PRINT AND ONLINE IN OCTOBER.



The ultimate guide
to making your
practice a success,

this exciting new publication

will be produced under the

direction of Editor-in-Chief Bernard M. Rosof, MD, MACP, North Shore Long Island Jewish Health System; Department of Medicine, SUNY Stony Brook School of Medicine; and Co-chair of the AMA Physician Consortium for Performance Improvement.

www.jfponline.com

FREE CME